Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Delgocitinib QTcF Prolongation Study in Healthy Subjects
NCT05050279Phase 1Completed
- Sponsor
- LEO Pharma
- Start
- Sep 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of delgocitinib in Eczema (5 arms), sponsored by LEO Pharma. Primary endpoint: Change from baseline QTcF at 24 hours. Started Sep 2021; status: completed.
02
Drugs
delgocitinib
03
Conditions
Eczema
Beyond the preview
Go deeper on NCT05050279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05050279.